T. Marbury - Concepedia

Author

T. Marbury

Orlando Clinical Research Center

Also Known As

T. Marbury, T.C. Marbury, TC Marbury

Publications

280

Citations

H-Index

Concepts

All Affiliations

Orlando Clinical Research Center Clinical Research Institute Seno Medical (United States)Hôpital Saint Eloi Avail Clinical Research

About

T. Marbury is an author at Orlando Clinical Research Center specializing in medicine, pharmacotherapy, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	256
2	Pharmacology	4	4	220
3	Immunology	2	2	36
4	Nephrology	2	2	198
5	Hepatology	1	1	11

T. Marbury

Publications

266

Citations

H-Index

Page 1

	Year	Citations
Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease Ronan Courtney, A Sansone, Winter J. Smith, The Journal of Clinical Pharmacology Healthy SubjectsDialysis TherapyClinical MycologyPharmacotherapyAntimicrobial Chemotherapy	2005	126
1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977 Melanie Cornpropst, Jill Denning, David Clemons, Journal of Hepatology HemodialysisUrologyRenal FunctionMedicineKidney Failure	2012	72
1186 SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS Eric Lawitz, T. Marbury, Andrew Campbell, Journal of Hepatology Antiviral CompoundNeurovirologyImmunologyAntiviral Drug DevelopmentHepatitis	2012	24
2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256 E.J. Lawitz, T. Marbury, Bradley Vince, Journal of Hepatology Viral HepatitisImmunologyAntiviral Drug DevelopmentHepatitisVirology	2010	12
1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS E.J. Lawitz, Jacqueline Hill, T. Marbury, Journal of Hepatology HepatologyViral HepatitisLiver PhysiologyMedicineAntiviral Drug Development	2012	11
1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885 Eric Lawitz, Daniel Gruener, John M. Hill, Journal of Hepatology Viral HepatitisPharmacologyAntiviral Drug DevelopmentHepatitisVirology	2011	11
876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS Andrew J. Muir, John M. Hill, E. Läwitz, Journal of Hepatology	2013	10

Page 1